Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

  • 5944 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von Abhängigkeit und Entzugssyndromen beschrieben. Der Aufbau dieses Kapitels unterscheidet sich insofern von den anderen Kapiteln als die einzelnen Suchtmittel die Struktur vorgeben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Andresen-Streichert H, Müller A, Glahn A et al (2018) Alkoholmarker bei klinischen und forensischen Fragestellungen. Dtsch Arztebl 115(18): 309–315

    Google Scholar 

  • Barrio P, Ortega L, Guardia J et al (2018) Who receives nalmefene and how does it work in the real world? A single-arm, phase IV study of nalmefene in alcohol dependent outpatients: baseline and 1-month results. Clin Drug Investig 38(2): 147–155

    Article  Google Scholar 

  • BMG (Bundesministerium für Gesundheit) (2017) https://www.bundesgesundheitsministerium.de/service/publikationen/drogen-und-sucht/details.html?bmg[pubid]=3104 (zuletzt abgerufen am 23.4.2018)

    Google Scholar 

  • Davies NM, Taylor GMJ, Taylor AE et al (2018) The effects of prescribing varenicline on two-year health outcomes: an observational cohort study using electronic medical records. Addiction 113(6): 1105–1116

    Article  Google Scholar 

  • Doran N, Dubrava S, Anthenelli RM (2018) Effects of varenicline, depressive symptoms, and region of enrollment on smoking cessation in depressed smokers. Nicotine Tob Res [Epub ahead of print]

    Google Scholar 

  • Foa EB, Yusko DA, McLean CP et al (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: A randomized clinical trial. JAMA 310: 488

    Article  CAS  Google Scholar 

  • Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W et al (2017) Methamphetamine-related disorders. Dtsch Arztebl Int 114(26): 455–461

    Google Scholar 

  • Heinzerling KG, Swanson AN, Hall TM et al (2014) Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 109(11): 1878–1886

    Article  Google Scholar 

  • Hoch E, Friemel CM, Schneider M (Hrsg) (2018) Cannabis: Potential und Risiko. Ergebnisse einer wissenschaftlichen Analyse. Springer, Berlin Heidelberg New York (im Druck)

    Google Scholar 

  • Hohmann N, Mikus G, Czock D (2014) Wirkungen und Risiken neuartiger psychoaktiver Substanzen. Dt Ärztebl 9: 139–147

    Google Scholar 

  • Kampman KM, Pettinati HM, Lynch KG et al (2013) A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 133(1): 94–99

    Article  CAS  Google Scholar 

  • Kishi T, Sevy S, Chekuri R, Correll CU (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. Clin Psychiatry 74(7): e642-54

    Article  Google Scholar 

  • Levin FR, Mariani J, Brooks DJ et al (2013) A randomized double-blind, placebo controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108(6): 1084–1094

    Article  Google Scholar 

  • Mann K, Aubin H-J, Charlet K, Witkiewitz K (2017) Can reduced drinking be a viable goal for alcohol dependent patients? World Psychiatry 16(3): 325–326

    Article  Google Scholar 

  • Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109(40): E2657–664

    Article  CAS  Google Scholar 

  • Palpacuer C, Duprez R, Huneau A et al (2017) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113(2): 220–237

    Article  Google Scholar 

  • Potenza MN (2017) Clinical neuropsychiatric considerations regarding nonsubstance or behavioral addictions. Dialogues Clin Neurosci 19(3): 281–291

    Google Scholar 

  • Rose JE, Behm FM (2014) Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 171(11): 1199–1205

    Article  Google Scholar 

  • Rüther T, Wissen F, Linhardt A et al (2016) Electronic cigarettes – attitudes and use in Germany. Nicotine Tob Res 18(5): 660–669

    Article  Google Scholar 

  • Shoptaw S, Huber A, Peck J et al (2006) Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 85(1): 12–18

    Article  CAS  Google Scholar 

  • Squeglia LM, Tomko RL, Baker NL et al (2018) The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend 185: 17–22

    Article  CAS  Google Scholar 

  • Sigmon SC, Dunn KE, Saulsgiver K et al (2013) A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70(12): 1347–1354

    Article  CAS  Google Scholar 

  • Soyka M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 17(4): 619–626

    Article  CAS  Google Scholar 

  • Stapleton J, West R, Hajek P et al (2013) Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 108(12): 2193–2201

    Article  Google Scholar 

  • Sullivan JT, Sykora K, Schneiderman J et al (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 84(11): 1353–1357

    Article  CAS  Google Scholar 

  • Tiihonen J, Krupitsky E, Verbitskaya E et al (2012) Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 169(5): 531–536

    Article  Google Scholar 

  • Verthein U, Beck T, Haasen C, Reimer J (2015) Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res 21(2): 97–104

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mannheim, Deutschland

    Prof. Dr. med. F. Kiefer

  2. Mainz, Deutschland

    Prof. Dr. med. O. Benkert

Authors
  1. Prof. Dr. med. F. Kiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to F. Kiefer or O. Benkert .

Editor information

Editors and Affiliations

  1. Mainz, Deutschland

    O. Benkert

  2. München, Deutschland

    H. Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Kiefer, F., Benkert, O. (2019). Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57334-1_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57333-4

  • Online ISBN: 978-3-662-57334-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation